Armata Pharmaceuticals’ (ARMP) “Buy” Rating Reaffirmed at HC Wainwright

Armata Pharmaceuticals (NYSEAMERICAN:ARMP)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $7.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 270.37% from the stock’s previous close.

Armata Pharmaceuticals Price Performance

ARMP stock traded down $0.06 during mid-day trading on Thursday, hitting $1.89. 10,713 shares of the company were exchanged, compared to its average volume of 12,196. The firm has a market cap of $68.38 million, a P/E ratio of -1.15 and a beta of 0.78. Armata Pharmaceuticals has a twelve month low of $1.89 and a twelve month high of $4.48.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.